Pregnenolone
Pregnenolone is an endogenous steroid synthesized from cholesterol and is the upstream precursor ("parent") of all other steroid hormones (progesterone, DHEA, androgens, estrogens, cortisol) and of neuroactive steroids such as allopregnanolone and pregnenolone sulfate. It is sold as an over-the-counter dietary supplement and is marketed for anti-aging, cognition, mood, "hormone support," and post-cycle recovery. Essentially none of those physique- or hormone-boosting claims are supported by human data. The only reasonably designed human trials studied it as an add-on to antipsychotics/antidepressants in schizophrenia and bipolar depression, with mixed and generally modest results; two meta-analyses disagree on whether it works at all. Because pregnenolone sits at the very top of steroidogenesis, oral dosing can in theory be converted into androgens, estrogens, progesterone or cortisol in an unpredictable, individual-specific way, and long-term safety, hormonal effects, and effects in healthy people using it for performance/anti-aging have not been adequately studied. Concerns include unstudied long-term hormonal consequences, theoretical risk in hormone-sensitive cancers, possible neuropsychiatric/sedative or activating effects, and false expectations that it "boosts testosterone" or restores the axis after anabolic steroid use (no evidence supports this). Use, if at all, only with a clinician and bloodwork.
Mechanism of action
Pharmacokinetics
Not reliably established in humans. Endogenous pregnenolone turns over rapidly and oral pregnenolone appears to be quickly metabolized; in a controlled bipolar-depression trial, dosing up to 500 mg/day produced large increases in downstream neurosteroids (allopregnanolone, pregnanolone) rather than large sustained increases in pregnenolone itself, indicating rapid conversion. No validated human oral half-life value is available (evidence D for PK).
Not established in humans. In trials it was given once daily or in divided/titrated doses over 8-12 weeks; a discrete duration of action has not been characterized.
Oral (capsules/tablets) as used in dietary supplements and in the clinical trials to date.
Metabolized in the liver, adrenal, gonadal, and brain tissue, where it serves as the substrate for steroidogenesis: converted via CYP17A1 to 17-OH-pregnenolone and DHEA, via 3-beta-HSD to progesterone, and to neurosteroids (allopregnanolone, pregnenolone sulfate). Because it feeds the whole steroid pathway, downstream conversion is variable between individuals and largely uncharacterized after oral supplementation. Human oral bioavailability is not well defined; the quantitative PK literature retrieved is preclinical (rodent) and largely concerns the related analog 16-dehydropregnenolone, not pregnenolone itself.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Adjunctive (add-on) use with antipsychotics has, in some 8-week RCTs, modestly reduced negative symptoms of schizophrenia/schizoaffective disorder (e.g., blunted affect, avolition, anhedonia) and improved some measures of attention/functional capacity; effects are inconsistent across trials.
- In a 12-week RCT of bipolar depression, add-on pregnenolone (titrated to 500 mg/day) improved some depression rating-scale outcomes versus placebo.
- Oral dosing raises circulating downstream neurosteroids (allopregnanolone, pregnanolone) in humans.
- No demonstrated benefit for cognition in most primary cognitive endpoints (composite cognitive battery scores generally did not improve).
- No human evidence that it increases testosterone, builds muscle, enhances athletic performance, reverses aging, or restores the hormonal axis after anabolic steroid use.
- Effects reported in healthy performance/anti-aging users are not supported by adequate controlled human data.
Adverse effects by system
No cardiovascular adverse signal was highlighted in the short (8-12 week) RCTs, but blood pressure, lipids, and cardiac endpoints were not systematically studied and there is no long-term or dedicated cardiovascular safety data. Effects are effectively unknown (no adequate human data).
No hepatotoxicity signal reported in short trials, and pregnenolone is not a 17-alpha-alkylated oral anabolic steroid, so the classic oral-AAS liver-toxicity mechanism does not apply. However, liver enzymes were not a systematic endpoint and there is no long-term hepatic safety data.
As the top precursor of steroidogenesis, oral pregnenolone can in theory be converted to androgens, estrogens, progesterone, or cortisol, so it could alter sex-hormone and possibly cortisol balance in an unpredictable, individual-specific manner. Whether oral supplementation meaningfully changes testosterone, estradiol, DHEA-S, or cortisol in humans has not been adequately established. It is not a known HPTA suppressant, but it is also not shown to support or restore the axis.
No direct human reproductive-outcome data. Through possible conversion to sex steroids, theoretical effects include menstrual changes, breast tenderness/gynecomastia (estrogenic) or virilizing effects (androgenic); none are established. Contraindicated in pregnancy/breastfeeding due to lack of safety data.
Studied populations were psychiatric patients; trials generally reported good tolerability without worsening of psychosis or mania, but because it modulates GABA-A and NMDA systems via neurosteroid metabolites, sedation, activation, mood changes, anxiety, or (theoretically) altered seizure threshold are plausible and warrant monitoring, especially unsupervised. Mania/hypomania was monitored in the bipolar trial without a clear signal, but caution is warranted.
No renal adverse effect or signal has been established; renal endpoints were not specifically studied (no adequate human data).
No hematologic adverse effect or signal established; hematologic parameters were not a systematic endpoint (no adequate human data).
No dermatologic adverse effect established. Given possible downstream androgen conversion, acne or oily skin is theoretically possible but not documented in the human literature (no adequate data).
HPTA suppression & recovery
Suppression: Not an established HPTA suppressant, but hormonal effects on the axis are unstudied and unpredictable
Pregnenolone is an upstream steroid precursor, not an anabolic androgen and not a selective estrogen receptor modulator (SERM), and it has not been shown to suppress the hypothalamic-pituitary-gonadal axis. Critically, it has also not been shown to raise testosterone or to restore/support the axis after anabolic steroid use, and it should not be used or relied upon as post-cycle therapy. Because it can theoretically be converted to androgens, estrogens, progesterone, or cortisol, its net effect on the axis in any given person is unknown. Anyone considering it for hormonal 'support' or recovery must involve an endocrinologist and rely on serial bloodwork rather than assuming benefit; it is not a substitute for medically supervised recovery. (Single-SERM note is not applicable: pregnenolone is not a SERM, and dual-SERM protocols are never recommended.)
Monitoring
Cadence: Baseline before starting; if used chronically, re-check hormonal and safety labs periodically (e.g., roughly every 3 months) and any time new symptoms appear; all monitoring should be directed by a clinician.
- New or worsening mood changes, agitation, anxiety, insomnia, or (in bipolar-spectrum individuals) manic/hypomanic symptoms
- Excess sedation or daytime somnolence
- Signs of estrogenic effect: breast tenderness or gynecomastia, unexplained menstrual changes
- Signs of androgenic effect: acne, oily skin, virilization, hair changes
- Any symptom suggestive of a hormone-sensitive condition (e.g., breast lump, abnormal bleeding, urinary changes) - stop and seek medical evaluation
Contraindications
- Hormone-sensitive cancers or history thereof (breast, prostate, ovarian, uterine/endometrial) due to theoretical conversion to sex steroids
- Pregnancy and breastfeeding (no safety data)
- Concurrent hormone therapy or other steroid/precursor supplements (unpredictable additive hormonal effects)
- Seizure disorders or use of drugs affecting seizure threshold (theoretical, via neurosteroid GABA-A/NMDA modulation)
- Serious psychiatric illness without specialist supervision
- Use as a self-directed testosterone booster or post-cycle therapy (no evidence of benefit; potential for harm and false reassurance)
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Do not expect pregnenolone to raise testosterone, build muscle, or restore your hormonal axis after anabolic steroid use - there is no human evidence for any of these, and using it for that purpose can create false reassurance and delay proper medical care.
- If you use it at all, involve a clinician and get baseline and periodic bloodwork (sex hormones, LH/FSH, and general safety labs); do not treat an OTC 'supplement' label as evidence of safety.
- Avoid entirely if you have or have had a hormone-sensitive cancer, are pregnant or breastfeeding, or are on other hormonal therapies or precursors.
- Because effects on mood are plausible via neurosteroid metabolites, stop and seek care if you develop significant mood changes, agitation, mania/hypomania, marked sedation, or new anxiety - especially if you have a psychiatric history.
- Stop and get evaluated for signs of hormonal effect (breast tenderness/gynecomastia, virilization, acne, menstrual changes) or any warning sign of a hormone-sensitive condition (breast lump, abnormal bleeding, urinary changes).
- Recognize that long-term safety is unknown - the human trials ran only 8-12 weeks; chronic self-use is uncharted territory.
- Never combine it with other steroid precursors or hormonal agents in an attempt to 'stack' hormonal effects.
Citations (12)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Pregnenolone is the neurosteroid precursor to allopregnanolone (positive GABA-A modulator) and pregnenolone sulfate (positive NMDA modulator), providing the mechanistic rationale in schizophrenia; preclinical actions include neuroprotection, promyelination, and enhanced learning/memory.
ReviewPMID 21756978 ↗
- 02
In an 8-week RCT (n=120 randomized) of adjunctive pregnenolone in schizophrenia, it did not improve composite cognitive scores but improved functional capacity (UPSA-B) versus placebo and was well tolerated.
- 03
In a 12-week RCT of bipolar depression (n=80), add-on pregnenolone titrated to 500 mg/day improved some depression outcomes versus placebo, was well tolerated, and produced large baseline-to-exit increases in downstream neurosteroids (allopregnanolone, pregnanolone).
- 04
In a pilot RCT in schizophrenia/schizoaffective disorder, adjunctive pregnenolone (titrated to 500 mg/day for 8 weeks) was well tolerated and significantly improved negative symptoms (SANS) versus placebo, with serum neurosteroid increases correlating with cognitive measures.
- 05
In an 8-week RCT comparing pregnenolone 30 mg/day, 200 mg/day, DHEA 400 mg/day, and placebo, low-dose pregnenolone (30 mg) improved positive symptoms, extrapyramidal side effects, attention, and working memory, while 200 mg did not differ from placebo; all treatments were well tolerated.
- 06
In an 8-week two-center RCT, adjunctive pregnenolone 50 mg/day significantly reduced negative symptoms in recent-onset schizophrenia/schizoaffective disorder and was well tolerated.
- 07
In an 8-week RCT, adjunctive pregnenolone 50 mg/day improved visual attention deficits in recent-onset schizophrenia/schizoaffective disorder.
- 08
In an 8-week RCT, pregnenolone 50 mg/day combined with L-theanine reduced negative and anxiety symptoms in schizophrenia/schizoaffective disorder and was well tolerated.
- 09
In an 8-week RCT in women with chronic schizophrenia (n=82), risperidone plus pregnenolone 50 mg/day did not produce a statistically significant benefit on total PANSS after correction for multiple testing.
- 10
A meta-analysis of anti-inflammatory adjuncts in schizophrenia reported significant cognitive improvement with pregnenolone (and minocycline) augmentation.
Meta-analysisPMID 30864461 ↗
- 11
A separate meta-analysis of anti-inflammatory agents in schizophrenia found that pregnenolone showed no significant effect on symptom severity, underscoring inconsistent efficacy.
Meta-analysisPMID 31439071 ↗
- 12
Oral steroid-precursor supplementation feeds the human steroidogenic pathway and can raise downstream steroids/neurosteroids (demonstrated for the related precursor DHEA raising androgens, estrogens, and allopregnanolone), supporting the concern that pregnenolone conversion is variable and pathway-wide.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice